Investors / United States / Polaris Partners
Polaris Partners
Venture capital · Boston, MA, United States · North America
Polaris Partners is an investment firm that backs healthcare and biotechnology companies, including digital health, consumer-centric businesses, patient and provider solutions, data science and analytics, and therapeutics and genomics. It also operates affiliate funds: Polaris Growth Fund, which supports profitable founder-owned technology companies, and Polaris Innovation Fund, which works with early-stage academic research.
Invests inHealthcare & Biotech
In its own wordshealthcarebiotechdigital healthlife sciencesgenomicstherapeutics
Your fit with Polaris Partners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsPolaris Partners lists 12 checked portfolio companies on its own site and is named in 13 funding rounds, 1 of them as lead. Its most frequent entry is Series A, 42% of the companies with a known first round. Its largest themes are Healthcare & Biotech (85%), Legal & Compliance (8%) and Fintech (8%). 100% of its companies are based in United States. It invests most often alongside Agent Capital, Andreessen Horowitz and Avego.
Counts come from funding rounds that name Polaris Partners, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 8% |
| Series A | 42% |
| Series B | 33% |
| Growth | 17% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 1 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 1 | 0 |
| '25 | 6 | 1 |
| '26 | 5 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 30th | 12 companies |
| Recent activity | 86th | 5 rounds in 12 months |
| Early stage | 54th | 8% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 94th | 85% in its largest sector |
| Reach | 19th | 1 country |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Agent Capital | 2 |
| Andreessen Horowitz | 2 |
| Avego | 2 |
| CRV | 2 |
| GV | 2 |
| Gaingels | 2 |
| KdT Ventures | 2 |
| Mission BioCapital | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers12100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 85% | 15% |
| Legal & Compliance | 8% | 2% |
| Fintech | 8% | 12% |
Co-investor network
who it backs companies with, and who they back togetherCompare Polaris Partners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Polaris Partners| Date | Company | Stage |
|---|---|---|
| 13 Oct 2026 | Series B | |
| 2 Jun 2026 | Series A | |
| 18 Mar 2026 | Series B | |
| 27 Jan 2026 | Series B | |
| 8 Jan 2026 | Series B | |
| 4 Nov 2025 | Series B | |
| 28 Oct 2025 | Series A | |
| 28 Oct 2025 | Series A Led |
Round details for Polaris Partners
Amounts, full round histories and every co-investor in Polaris Partners' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
12 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Cirrus Therapeutics is developing therapies to treat age-related macular degeneration (AMD) by leveraging ocular immunology | Healthcare & Biotech | Oct 2025Seed | Funding round | |
| Crossbow Therapeutics develops antibody therapeutics to treat cancer. | Healthcare & Biotech | Mar 2026Series B | Funding round | |
| Dyno Therapeutics builds genetic technologies to unlock the potential of next-gen medicine | Healthcare & Biotech | May 2021Series A | Funding round | |
| EpiBiologics develops medicines that use bispecific antibodies to selectively degrade disease-causing extracellular proteins | Healthcare & Biotech | Jan 2026Series B | Funding round | |
| Freenome develops blood-based screening tests to detect cancer at its earliest stages | Healthcare & Biotech | Feb 2024Series C+ | Funding round | |
| Indomo is developing a fast-acting at-home solution for inflammatory acne lesions using a novel intradermal self-injection device and a drug candidate. | Healthcare & Biotech | Oct 2025Series A | Funding round | |
| The company provides online notary services, allowing users to upload documents, verify their identity, and connect with a notary online. | Legal & ComplianceFintech | Oct 2025Series C+ | Funding round | |
| Soufflé Therapeutics creates oligonucleotide therapies that target and enter cells causing a patient's disease. | Healthcare & Biotech | Oct 2025Series A · 2 rounds | Funding round | |
| Sovato develops a platform for remote robotic surgery and procedures | Healthcare & Biotech | Nov 2025Series B | Funding round | |
| Tavo Biotherapeutics is a biotech company developing novel treatments for glaucoma and retinal diseases. | Healthcare & Biotech | Jun 2026Series A | Funding round | |
| TRexBio is developing immunoregulatory medicines for autoimmune and inflammatory diseases. | Healthcare & Biotech | Jan 2026Series B | Funding round | |
| Zag Bio develops therapies that target the thymus to treat autoimmune diseases by restoring balance to the immune system. | Healthcare & Biotech | Oct 2025Series A | Funding round |
About this data
site last read 11 Nov 2026- Site
- polarispartners.com
- Last read
- 11 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 6 May 2021
- Companies checked
- 12
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Polaris Partners' profile as data
Pull Polaris Partners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/polarispartners.com
# also
GET /v1/firms/polarispartners.com/portfolio
GET /v1/firms/polarispartners.com/coinvestors
GET /v1/firms/polarispartners.com/news